Global Cancer Companion Diagnostic Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cancer Companion Diagnostic Market Insights, Forecast to 2034
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
Market Analysis and InsightsGlobal Cancer Companion Diagnostic Market
Global Cancer Companion Diagnostic market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Cancer Companion Diagnostic industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
Report Covers
This report presents an overview of global Cancer Companion Diagnostic market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Cancer Companion Diagnostic market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Cancer Companion Diagnostic introduction, etc. Cancer Companion Diagnostic Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Cancer Companion Diagnostic
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Cancer Companion Diagnostic Market
Global Cancer Companion Diagnostic market is expected to reach to US$ million in 2023, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, Cancer Companion Diagnostic industry is evaluated to reach US$ million in 2033. The CAGR will be % during 2023 to 2033.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
Report Covers
This report presents an overview of global Cancer Companion Diagnostic market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Cancer Companion Diagnostic market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
AmoyDx
Novogene
Illumina
Roche
Agilent
Abbott
Thermo Fisher
Qiagen
Guardant Health
Segment by Type
Polymerase Chain Reaction (PCR)
“Next Generation” Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Cancer Companion Diagnostic introduction, etc. Cancer Companion Diagnostic Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Cancer Companion Diagnostic
Chapter 13Methodology and Data Sources adopted by MRAResearch
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices